Thanks to advancements in phacoemulsification technology, surgeons can preset intraocular pressure (IOP) settings to be maintained throughout #CataractSurgery. This video by #Alcon summarizes a study evaluating the impact of operating at physiologic vs high IOP.

Do trifocal intraocular lenses made from a hydrophobic acrylic material meet the increasingly high expectations of today’s cataract surgery patients? In this video, Dr. Lillie Mosaddegh discusses refractive, visual and satisfaction outcomes. Watch now: bit.ly/41usZ4X

BIG NEWS: TRYPTYR® (acoltremon ophthalmic solution 0.003%) has officially been approved by the United States Food and Drug Administration (#FDA) for the treatment of signs and symptoms of DED. See the science: bit.ly/4jvGM0R #AlconScience #MedicalAffairs #AlconUS

In a recent roundtable discussion, 4 surgeons shared their personal experiences with performing #CataractSurgery at standard, higher intraocular pressures (IOPs) of ≥60 mmHg as well as lower, near-physiologic IOPs of ≤30 mmHg. Review their discussion here:

Watch this video from #Alcon Global Medical Affairs to see how using an active-fluidics phacoemulsification system to maintain near-physiologic intraocular pressure of ≤28 mmHg during #CataractSurgery affects surgical efficiency and ocular tissue: spr.ly/601445Yir

#Alcon study spotlight: #Glaucoma and ocular hypertension patients who added Rho-kinase inhibitor netarsudil to another intraocular pressure (IOP)-lowering agent of a different class experienced mean IOP reductions of 20.5 and 20.9% respectively. bit.ly/42xZfUb

Discover the Alcon Investigator-Initiated Trial Program: Independent clinical research conducted by qualified investigators, supported by Alcon. Explore the program and our designated research areas of interest here: bit.ly/442K1Zq #AlconScience #MedicalAffairs

Review an #Alcon roundtable discussion between Doctors Cathleen McCabe, Zaina Al-Mohtaseb, John Hovanesian and Matthew Rauen about the impact of intraocular pressure on #CataractSurgery efficiency, postoperative ocular health and more: spr.ly/60152dS0X

Attention #DryEye disease (DED) specialists: See the latest research on DED, including approved treatments and breakthrough innovations, explore the pharmaceutical section of AlconScience.com: bit.ly/48sGO5P #AlconScience #MedicalAffairs #Ophthalmology #Optometry

Now on #Eyetube: Dive into Alcon’s latest innovations with easy-to-search videos by therapeutic area, practitioner, or product. #Alcon #MedicalAffairs Visit Alcon Science on Eyetube: bit.ly/4cHszML

Depending on the length of the eye, some newer intraocular lens (IOL) power calculation formulas may provide better outcomes when axial length is measured via the Sum-of-Segments rather than the Mean Group Refractive Index method. See why—spr.ly/60132ayit #CataractSurgery

Attention clinical researchers: Whether you practice in a private setting or an academic center, we welcome the opportunity to connect regarding our #Alcon Investigator-Initiated Trial Program. Learn more here: bit.ly/442K1Zq #AlconScience #MedicalAffairs

This paper from #Alcon Global Medical Affairs provides an overview of the Sum-of-Segments (SOS) and Mean Group Refractive Index methods for axial length (AL) measurement, as well as the impact of each method on intraocular lens (IOL) power calculations: spr.ly/60132ayYL

Planning to attend #APACRS2025? Visit our #Alcon #GlobalMedicalAffairs team at booth A1! This year’s theme, Learning from the Masters, perfectly captures our mission to share the latest scientific innovations in #CataractSurgery. bit.ly/3JfFQkT #AlconScience

Add #AlconScience Science on #Eyetube to your phone’s home screen for quick access to expert videos and research. Tap “Add to Home Screen” to keep Alcon Science Eyetube just one click away. #MedicalAffairs Visit Alcon Science on Eyetube: bit.ly/4cHszML

Don’t forget to check out our scientific exchange presentations at #APACRS2025. We’ll be the latest data generated on Vivity®, Clareon®, Monofocal, Clareon®, PanOptix®, UNITY®, VCS|CS, and Wavelight® plus. Register now to attend: bit.ly/3JfFQkT and visit booth A1 to

In recent phase 3 clinical trials, acoltremon 0.003% ophthalmic solution demonstrated effectiveness in increasing tear production. For more information about acoltremon ophthalmic solution 0.003%, visit alconscience.com. bit.ly/4mEE3En #AlconScience #Innovation

#APACRS2025 is coming up fast! If you’re planning to attend, sign up now for the #Alcon #GlobalMedicalAffairs symposium — Vivity IOL: A True EDOF IOL with Proven Real-World Performance — featuring expert surgeons Dr. Vaishali Vasavada, Dr. Ruth Lapid-Gortzak, and Dr. Hiroko

#APACRS2025 is now underway! From masterclasses and symposia to curated scientific exchange sessions and networking opportunities, it’s an ideal knowledge-sharing hub for the #Alcon #GlobalMedicalAffairs team. Don't miss our symposium — Vivity IOL: A True EDOF IOL with Proven